These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 16574742)
21. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075 [TBL] [Abstract][Full Text] [Related]
22. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938 [TBL] [Abstract][Full Text] [Related]
23. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219 [TBL] [Abstract][Full Text] [Related]
24. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. Xing RH; Rabbani SA Endocrinology; 1999 Sep; 140(9):4056-64. PubMed ID: 10465276 [TBL] [Abstract][Full Text] [Related]
25. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. Pakneshan P; Xing RH; Rabbani SA FASEB J; 2003 Jun; 17(9):1081-8. PubMed ID: 12773490 [TBL] [Abstract][Full Text] [Related]
26. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342 [TBL] [Abstract][Full Text] [Related]
27. Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase Alpha-mediated mechanism. Wada S; Udagawa N; Nagata N; Martin TJ; Findlay DM Endocrinology; 1996 Jan; 137(1):312-20. PubMed ID: 8536630 [TBL] [Abstract][Full Text] [Related]
28. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Hoosein NM; Boyd DD; Hollas WJ; Mazar A; Henkin J; Chung LW Cancer Commun; 1991 Aug; 3(8):255-64. PubMed ID: 1653586 [TBL] [Abstract][Full Text] [Related]
29. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms. Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763 [TBL] [Abstract][Full Text] [Related]
30. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751 [TBL] [Abstract][Full Text] [Related]
31. Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. Shah GV; Muralidharan A; Gokulgandhi M; Soan K; Thomas S J Biol Chem; 2009 Jan; 284(2):1018-30. PubMed ID: 19001380 [TBL] [Abstract][Full Text] [Related]
32. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553 [TBL] [Abstract][Full Text] [Related]
33. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623 [TBL] [Abstract][Full Text] [Related]
34. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Igawa T; Lin FF; Rao P; Lin MF Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404 [TBL] [Abstract][Full Text] [Related]
35. Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. Jarrard DF; Hansen NM; Patai B; Rukstalis DB Invasion Metastasis; 1995; 15(1-2):34-45. PubMed ID: 7672930 [TBL] [Abstract][Full Text] [Related]
37. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice. Zhao Z; He J; Kang R; Zhao S; Liu L; Li F Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693 [TBL] [Abstract][Full Text] [Related]
38. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875 [TBL] [Abstract][Full Text] [Related]
39. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. Robbins EW; Travanty EA; Yang K; Iczkowski KA BMC Cancer; 2008 Sep; 8():260. PubMed ID: 18793421 [TBL] [Abstract][Full Text] [Related]
40. [Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro]. Su J; You JF; Wang JL; Cui XL; Fang WG; Zheng J Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):404-7. PubMed ID: 19024511 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]